Targeting osseous metastases: rationale and development of radioimmunotherapy for prostate cancer

[1]  S. Vallabhajosula,et al.  Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. , 2003, The Journal of urology.

[2]  N. Bander,et al.  Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. , 2003, Seminars in oncology.

[3]  S. Vallabhajosula,et al.  Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  M. Rubin,et al.  Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. , 2002, Cancer research.

[5]  V. Reuter,et al.  HER‐2 profiling and targeting in prostate carcinoma , 2002, Cancer.

[6]  C. Cordon-Cardo,et al.  HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  G. Denardo,et al.  Radioimmunotherapy with 111in/90y-2it-BAD-m170 for metastatic prostate cancer , 2001 .

[8]  E. Small,et al.  Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Zlotta,et al.  Can survival be prolonged for patients with hormone-resistant prostate cancer? , 2001, The Lancet.

[10]  Terry L. Smith,et al.  Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial , 2001, The Lancet.

[11]  V. Gebski,et al.  Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer , 2001, British Journal of Cancer.

[12]  P. Kantoff,et al.  Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Cordon-Cardo,et al.  An α-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer , 2000 .

[14]  N. Bander,et al.  In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. , 2000, Cancer research.

[15]  M. Loda,et al.  Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer , 2000, Oncogene.

[16]  H. Scher,et al.  Clinical states in prostate cancer: toward a dynamic model of disease progression. , 2000, Urology.

[17]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[18]  D. Heitjan,et al.  Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. J. van Rensburg,et al.  Quantifying the radiation dosage to individual skeletal lesions treated with samarium-153-EDTMP. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  R. Lerski,et al.  Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Larson,et al.  Interferon-gamma and monoclonal antibody 131I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  M. Loda,et al.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Guise,et al.  Cancer and bone. , 1998, Endocrine reviews.

[24]  S. Nilsson,et al.  Radioimmunoscintigraphy with a novel monoclonal antiprostate antibody (E4) , 1997, Cancer.

[25]  N. Bander,et al.  Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. , 1997, Cancer research.

[26]  P. Schellhammer,et al.  Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. , 1996, Urology.

[27]  M. Goris,et al.  Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  T. Visakorpi,et al.  Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. , 1996, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[29]  D. F. Preston,et al.  Strontium 89 therapy for the palliation of pain due to osseous metastases. , 1995, JAMA.

[30]  K. Ow,et al.  The prognostic significance of tumor-associated markers p53, HER-2/neu, c-myc, v-H-ras, PCNA and EGFr of local and distant recurrence in localized human prostatic adenocarcinoma. , 1995, Urologic oncology.

[31]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[32]  V. Reuter,et al.  TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49. , 1995, The Journal of urology.

[33]  S. Larson,et al.  Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  P. Schellhammer,et al.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. , 1995, Urologic oncology.

[35]  H I Scher,et al.  Bone metastases: improving the therapeutic index. , 1994, Seminars in oncology.

[36]  J. Schlom,et al.  Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas. , 1994, The Journal of urology.

[37]  J. Schlom,et al.  Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[38]  C. Chapman,et al.  Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[39]  Mason,et al.  Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group. , 1993, Seminars in oncology.

[40]  J. Crook,et al.  Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. , 1993, International journal of radiation oncology, biology, physics.

[41]  S. Gallinger,et al.  Comparative dual label study of first and second generation antitumor-associated glycoprotein-72 monoclonal antibodies in colorectal cancer patients. , 1993, Cancer research.

[42]  W. Fair,et al.  Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. , 1993, Cancer research.

[43]  M. Campbell,et al.  Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. , 1992, Cancer research.

[44]  E. Paus,et al.  89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes. , 1992, British Journal of Cancer.

[45]  A. McEwan,et al.  A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. , 1991, European journal of cancer.

[46]  J. Schlom,et al.  Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. , 1988, Cancer research.

[47]  M. Unger,et al.  Scintigraphy with In-111-labeled monoclonal antitumor antibodies: kinetics, biodistribution, and tumor detection. , 1988, Radiology.

[48]  D. Carlo,et al.  Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276. , 1987, The Journal of urology.

[49]  A. Thor,et al.  Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. , 1986, Cancer research.